IL137766A0 - Strategically modified hepatitis b core proteins and their derivatives - Google Patents

Strategically modified hepatitis b core proteins and their derivatives

Info

Publication number
IL137766A0
IL137766A0 IL13776699A IL13776699A IL137766A0 IL 137766 A0 IL137766 A0 IL 137766A0 IL 13776699 A IL13776699 A IL 13776699A IL 13776699 A IL13776699 A IL 13776699A IL 137766 A0 IL137766 A0 IL 137766A0
Authority
IL
Israel
Prior art keywords
modified
modified hepatitis
derivatives
hepatitis
core proteins
Prior art date
Application number
IL13776699A
Other languages
English (en)
Original Assignee
Immune Complex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Complex Corp filed Critical Immune Complex Corp
Publication of IL137766A0 publication Critical patent/IL137766A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/795—Composed of biological material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/894—Manufacture, treatment, or detection of nanostructure having step or means utilizing biological growth
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine
IL13776699A 1998-02-12 1999-02-11 Strategically modified hepatitis b core proteins and their derivatives IL137766A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7453798P 1998-02-12 1998-02-12
PCT/US1999/003055 WO1999040934A1 (en) 1998-02-12 1999-02-11 Strategically modified hepatitis b core proteins and their derivatives

Publications (1)

Publication Number Publication Date
IL137766A0 true IL137766A0 (en) 2001-10-31

Family

ID=22120092

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13776699A IL137766A0 (en) 1998-02-12 1999-02-11 Strategically modified hepatitis b core proteins and their derivatives
IL137766A IL137766A (en) 1998-02-12 2000-08-08 Core proteins that have been modified from the hepatitis B virus and their derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL137766A IL137766A (en) 1998-02-12 2000-08-08 Core proteins that have been modified from the hepatitis B virus and their derivatives

Country Status (20)

Country Link
US (1) US6231864B1 (xx)
EP (1) EP1054689B1 (xx)
JP (1) JP4480268B2 (xx)
KR (1) KR100581991B1 (xx)
CN (1) CN100387622C (xx)
AT (1) ATE249240T1 (xx)
AU (1) AU767144B2 (xx)
BR (1) BR9907855A (xx)
CA (1) CA2320488C (xx)
CZ (1) CZ302092B6 (xx)
DE (1) DE69911175T2 (xx)
DK (1) DK1054689T3 (xx)
ES (1) ES2207177T3 (xx)
HK (1) HK1038306A1 (xx)
ID (1) ID26669A (xx)
IL (2) IL137766A0 (xx)
NZ (1) NZ506245A (xx)
PT (1) PT1054689E (xx)
TR (1) TR200002338T2 (xx)
WO (1) WO1999040934A1 (xx)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ES2317711T3 (es) 1998-11-30 2009-04-16 Cytos Biotechnology Ag Presentacion molecular de alergenos, metodos de preparacion y uso.
US6887464B1 (en) * 1999-02-02 2005-05-03 Biocache Pharmaceuticals, Inc. Advanced antigen presentation platform
AU2977500A (en) * 1999-02-02 2000-08-25 Biocache Pharmaceuticals, Llc Advanced antigen presentation platform
WO2001016174A2 (en) * 1999-08-30 2001-03-08 Rolf Kiessling Induction of cytotoxic t lymphocyte response by hla class ia restricted epitopes of mycobacterial heat shock protein 65
EP1265915B1 (en) 2000-02-23 2010-11-10 GlaxoSmithKline Biologicals s.a. Novel compounds
CA2407897A1 (en) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
EP1319069B1 (en) 2000-06-28 2008-05-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US6942866B2 (en) * 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
WO2002062959A2 (en) * 2001-02-05 2002-08-15 Stressgen Biotechnologies Corp. Hepatitis b virus treatment
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20040146524A1 (en) * 2002-02-21 2004-07-29 Katelynne Lyons Stabilized immunogenic HBc chimer particles
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine
US20030037327A1 (en) * 2001-08-15 2003-02-20 International Business Machines Corporation Run-time rule-based topological installation suite
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
DK1450856T3 (da) 2001-09-14 2010-05-31 Cytos Biotechnology Ag Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse
EP1425040A2 (en) * 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US7115266B2 (en) * 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
BR0213117A (pt) 2001-10-05 2004-09-21 Cytos Biotechnology Ag Conjugados peptìdeo angiotensina-veìculo e seus usos
ES2405790T3 (es) 2001-12-17 2013-06-03 Corixa Corporation Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
WO2003066833A2 (en) * 2002-02-08 2003-08-14 New York University Use of recombinant hepatitis b core particles to develop vaccines against infectious pathogens and malignancies
EP1517702A4 (en) * 2002-02-21 2006-05-03 Apovia Inc IMMUNOGENIC HBC CHIMERIC PARTICLES STABILIZED WITH AN N-TERMINAL END CYSTEINE
AU2003215395A1 (en) * 2002-02-21 2003-09-09 Apovia, Inc. STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
WO2003072722A2 (en) * 2002-02-21 2003-09-04 Apovia, Inc. IMMUNOGENIC AVIAN HBc CHIMER PARTICLES HAVING ENHANCED STABILITY
AU2003242742B2 (en) * 2002-06-20 2009-04-30 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
AU2003246690B2 (en) 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
IL165249A0 (en) 2002-07-18 2005-12-18 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
JP4644488B2 (ja) * 2002-07-19 2011-03-02 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト アミロイドベータ１−６抗原アレイを含むワクチン組成物
CN100560719C (zh) 2003-03-26 2009-11-18 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
WO2004102198A2 (en) * 2003-05-15 2004-11-25 Cytos Biotechnology Ag Selection of b cells with specificity of interest: method of preparation and use
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
WO2005014650A2 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US7144712B2 (en) 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
AU2004260665B2 (en) * 2003-07-30 2007-11-15 Vlp Biotech, Inc. Hepatitis virus core proteins as vaccine platforms and methods of use thereof
US7320795B2 (en) 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
CN1305527C (zh) * 2003-11-21 2007-03-21 薛平 乙型肝炎治疗疫苗及其制备方法
CA2553594A1 (en) * 2004-01-20 2005-07-28 Cytos Biotechnology Ag Particle-induced ghrelin immune response
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
CA2567597C (en) 2004-05-25 2014-03-18 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
US7964196B2 (en) * 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
ATE460922T1 (de) * 2006-04-07 2010-04-15 Chimeros Inc Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
EP2010226B1 (en) 2006-04-07 2014-01-15 The Research Foundation of State University of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
EP2134740A2 (en) * 2007-04-09 2009-12-23 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
GB0713880D0 (en) * 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
WO2009029272A2 (en) * 2007-08-27 2009-03-05 Agadjanyan Michael G Epitope vaccine for prevention and reversion of ad pathology
EP2240199A4 (en) * 2008-02-09 2012-10-03 Sanofi Pasteur Biologics Llc INFLUENZA VACCINES
CN101423555B (zh) * 2008-11-14 2011-04-20 四川大学华西医院 特异性阻断乙肝病毒组装和复制的膜穿透性多肽
CA2744754A1 (en) 2008-12-09 2010-06-17 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP2391383B1 (en) 2009-02-02 2015-12-23 ChronTech Pharma AB Codon-optimized hepatitis b virus core antigen (hbcag)
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
IN2012DN00446A (xx) * 2009-07-30 2015-05-15 Pfizer Vaccines Llc
ES2670576T3 (es) 2009-09-03 2018-05-31 Pfizer Vaccines Llc Vacuna de PCSK9
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP2672991B1 (en) 2011-02-12 2017-07-19 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
CA2837651A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
WO2013036973A2 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
CA2882563C (en) * 2012-08-21 2022-11-29 Eric Hryhorenko Antibodies to risperidone haptens and use thereof
CA2936092A1 (en) 2013-01-23 2014-07-31 The Board Of Trustees Of The Leland Stanford Junior University Stabilized hepatitis b core polypeptide
WO2014144775A2 (en) 2013-03-15 2014-09-18 Vlp Biotech, Inc. Rodent hepadnavirus cores with reduced carrier-specific antigenicity
CA2906770A1 (en) * 2013-03-15 2014-09-18 Vlp Biotech, Inc. Palivizumab epitope-based virus-like particles
GB201402890D0 (en) 2014-02-18 2014-04-02 Iqur Ltd Vaccines based on hepatitis B Core antigens
CN104208670B (zh) * 2014-09-09 2017-07-28 韩自勤 一种治疗乙肝的药物组合物
GB201505041D0 (en) * 2015-03-25 2015-05-06 Iqur Ltd Vaccines based on hepatitis B core antigens
CN107383176A (zh) * 2017-05-10 2017-11-24 于学杰 用于对汉滩病毒和汉城病毒引起的肾综合征出血热分型的多肽
SG11201912454SA (en) * 2017-06-23 2020-01-30 American Type Culture Collection Atcc Virus-like particles comprising zika antigen
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
US20220118077A1 (en) 2018-09-11 2022-04-21 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
US20210047425A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
CN110804097B (zh) * 2019-10-30 2021-02-26 云南沃森生物技术股份有限公司 一种同时制备两种单克隆抗体的方法
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023057567A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Pd-l1 binding affimers
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ192465A (en) 1978-12-22 1983-09-30 Biogen Nv Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
GB8903313D0 (en) * 1989-02-14 1989-04-05 Wellcome Found Conjugates
NZ235315A (en) * 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
US5840303A (en) * 1991-08-26 1998-11-24 The Scripps Research Foundation Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
JP2001500012A (ja) * 1996-09-03 2001-01-09 ザ ジェネラル ホスピタル コーポレーション ウイルス複製の阻害

Also Published As

Publication number Publication date
AU2675399A (en) 1999-08-30
TR200002338T2 (tr) 2002-06-21
ATE249240T1 (de) 2003-09-15
CZ20002819A3 (en) 2001-06-13
ID26669A (id) 2001-01-25
BR9907855A (pt) 2001-04-24
DK1054689T3 (da) 2004-01-26
NZ506245A (en) 2003-08-29
CA2320488C (en) 2007-03-06
AU767144B2 (en) 2003-10-30
CN1300222A (zh) 2001-06-20
EP1054689A1 (en) 2000-11-29
DE69911175T2 (de) 2004-07-29
JP4480268B2 (ja) 2010-06-16
WO1999040934A1 (en) 1999-08-19
CN100387622C (zh) 2008-05-14
EP1054689A4 (en) 2002-02-13
CA2320488A1 (en) 1999-08-19
ES2207177T3 (es) 2004-05-16
IL137766A (en) 2007-12-03
KR100581991B1 (ko) 2006-05-23
CZ302092B6 (cs) 2010-10-06
HK1038306A1 (en) 2002-03-15
KR20010052165A (ko) 2001-06-25
JP2002509700A (ja) 2002-04-02
DE69911175D1 (de) 2003-10-16
PT1054689E (pt) 2003-11-28
US6231864B1 (en) 2001-05-15
EP1054689B1 (en) 2003-09-10

Similar Documents

Publication Publication Date Title
HK1038306A1 (en) Strategically modified hepatitis b core proteins and their derivatives
NO932644L (no) Antigen-presenterende kapsid med fusert ms2-kappeprotein
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
WO1993001210A3 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
GB2191690A (en) Air support for chairs, chair utilizing the same and method of manufacturing the same
CA2078694A1 (en) Hepatitis b vaccine
IE822084L (en) Preparation of polypeptides in vertebrate cell culture
MXPA02007733A (es) Mejoramiento de la vida media circulante de proteinas de fusion basadas en anticuerpos.
ZA853025B (en) Isolation of proteins of htlv-iii,serological detection of antibodies to htlv-iii in sera of patients with aids and pre-aids conditions,and detection of htlv-iii infection by immuno-assays using htlv-iii and its proteins
IE900502L (en) Conjugates
ES8702949A1 (es) Procedimiento para la produccion de anticuerpos monoclonales a ciclosporinas.
HK166495A (en) HIV-1 envelope muteins lacking hypervariable domains
NO884741D0 (no) Amfotericin b/kolesterolsulfatpreparat og fremgangsmaate for fremstilling derav.
MX9603182A (es) Vacuna de hepatitis b.
EP0540645A4 (en) Methods of use of bovine respiratory syncytial virus recombinant dna, proteins vaccines, antibodies, and transformed cells
CA2019218A1 (en) Magnetic protein conjugates, a process for the preparation thereof and the use thereof
AU1908395A (en) Antibodies to mammalian natural killer antigens and uses
JPS6463392A (en) Monoclonal antibody against specific antigen for human immunodeficiency virus
DE3888887D1 (de) Monoklonale Antikörper gegen E7-Protein des Humanen Papillomvirus Typ 16, Verfahren zu ihrer Herstellung sowie ihre Verwendung.
WO2002012535B1 (en) Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotherapy
EP0836484A4 (en) IN-VITRO PACKING OF ADENO-ASSOCIATED VIRUS DNA
JPS5328164A (en) Maleimide derivatives
EP0503252A3 (en) Recombinant proteins having the immunoreactivity of hepatitis b virus e antigens (hbeag), method for their production and their application in immunoassays and as vaccines
JPS5616415A (en) Preparation of antibody
AU8217487A (en) Process for the cultivation of mammalian cells in a suspension culture, device for carrying out the process, and use for the preparation of proteins

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed